Steve Scala
Stock Analyst at TD Cowen
(2.77)
# 1,771
Out of 5,115 analysts
33
Total ratings
74.07%
Success rate
13.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Hold | $100 → $120 | $110.27 | +8.82% | 2 | Jan 20, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $41.68 | +7.97% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $223.01 | +0.89% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $55.05 | +7.18% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $92.77 | +2.40% | 1 | Aug 12, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $26.44 | +21.03% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $1,037.15 | -51.79% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $148.68 | -29.38% | 4 | Feb 1, 2021 |
Merck & Co.
Jan 20, 2026
Maintains: Hold
Price Target: $100 → $120
Current: $110.27
Upside: +8.82%
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $41.68
Upside: +7.97%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $223.01
Upside: +0.89%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $55.05
Upside: +7.18%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $92.77
Upside: +2.40%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $26.44
Upside: +21.03%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $1,037.15
Upside: -51.79%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $148.68
Upside: -29.38%